GSK files for European approval of diabetes drug
Research Triangle Park, N.C. —
Albiglutide, which will go by the name Eperzan, is an investigational injectible treatment for adults with type 2 diabetes. The drug is expected to compete against other injectible diabetes drugs, including Novo Nordisk’s daily injectible drug Victoza. GSK expects its once-weekly albiglutide will offer a dosing advantage.
Albiglutide was discovered and developed by Human Genome Sciences, which partnered with GSK on the compound. GSK last year acquired Human Genome Sciences in a $3.6 billion takeover. The compound is not not yet approved anywhere in the world but the drug maker has already taken steps to secure U.S. approval. GSK made its albiglutide regulatory filing to the Food and Drug Administration in January.
London-based GSK operates its U.S. headquarters in Research Triangle Park.
Please log in to view WRALTechWire Insider content
Please Log In to add a comment.
Best of TechWire Insider
- NC Biotech Center braces for worst as Senate slashes budget, too
- ArchiveSocial, a new Durham success story, brings home international award
- Durham's high-tech infrastructure, talent lure Virginia company
- Lenovo acknowledges layoffs in Morrisville as part of shift to 'PC Plus' strategy
- Raleigh-based PRA International eyes public offering
- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows